CAR-NK cells to treat patients with cancer: a systematic scoping review of published studies and registered clinical trials
The clinical outcomes and low adverse event rates following CAR-NK therapy in published studies are encouraging. Larger controlled trials are needed to confirm the safety and efficacy of CAR-NK therapy. We anticipate the completion of several such trials in the coming years.
Authors
- Matthew D. Seftel (ORCID: https://orcid.org/0000-0002-0960-2687)
- Aidan M. Kirkham (ORCID: https://orcid.org/0000-0001-6432-3018)
- Shehroz Rana
- Risa Shorr (ORCID: https://orcid.org/0000-0003-0388-5812)
- Harinad B. Maganti (ORCID: https://orcid.org/0000-0001-5395-4009)
- Alissa Visram (ORCID: https://orcid.org/0000-0002-7201-4642)
- David Allan (ORCID: https://orcid.org/0000-0003-3261-8289)
- L. Thomas
Institutions
- University of Ottawa (CA)
- Ottawa Hospital (CA)
- Ottawa Hospital Research Institute (CA)
- Canadian Blood Services (CA)
Publication Details
- Journal
- Cytotherapy
- Published
- 2025-06-13
- DOI
- https://doi.org/10.1016/j.jcyt.2025.06.006
- Citations
- 7
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 7.32
Funders
- Canadian Blood Services